OncLive TV

Eric Shinohara, MD, MSCI, discusses the future of stereotactic body radiation and surgery in prostate cancer.

Thomas G. Martin, MD, discusses the use of selinexor in patients with triple-class refractory multiple myeloma.

A. Oliver Sartor, MD, discusses research on immunotherapy, radiopharmaceuticals, and combinations in prostate cancer.

Ilaria Iacobucci, PhD, discusses integrated transcriptomic and genomic sequencing to identify prognostic constellations of driver mutations in AML and MDS.

Sara M. Tolaney, MD, MPH, discusses the advantages of circulating tumor DNA versus tissue biopsy in breast cancer.

David F. Penson, MD, MPH, MMHC, discusses questions regarding next-generation androgen receptor (AR) inhibitors in prostate cancer.

Manish Kohli, MD, discusses drugs that have been evaluated in metastatic castration-resistant prostate cancer.

Casey M. Cosgrove, MD, discusses the approval of niraparib in advanced ovarian cancer.

Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses ongoing research with pacritinib in myelofibrosis.

Clara Hwang, MD, a medical oncologist with Henry Ford Health System, discusses treatment selection in newly diagnosed metastatic castration-sensitive prostate cancer (mCSPC).

Bita Fakhri, MD, MPH, assistant professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the use of PI3K inhibitors in relapsed/refractory chronic lymphocytic leukemia (CLL).

R. Steven Paulson, MD, discusses molecular testing in oncology.

Christopher A. Yasenchak, MD, discusses brentuximab vedotin (Adcetris) plus nivolumab (Opdivo) in patients with Hodgkin lymphoma.

Jonathan E. Brammer, MD, discusses the progression of transplant in acute lymphoblastic leukemia.

Sreeni Chittoor, MD, FACP, discusses targetable mutations and respective treatment options for patients with metastatic non–small cell lung cancer.

Benjamin P. Levy, MD, discusses biomarkers for immunotherapy in lung cancer.

Mika Cline, MD, discusses data with PARP inhibitors in patients with BRCA1/2 mutated pancreatic cancer.

Peter Voorhees, MD, discusses the updated depth of response data that were reported in the GRIFFIN trial of patients with multiple myeloma.

Refaat Hegazi, MD, PhD, MPH, discusses nutrition-related toxicities in oncology.

Madhuri Vusirikala, MD, discusses the role of minimal residual disease in acute lymphoblastic leukemia.

Elisabeth I. Heath, MD, FACP, discusses a remaining challenge in nonmetastatic castration-resistant prostate cancer.

Floor J. Backes, MD, discusses toxicity considerations with PARP inhibitors in ovarian cancer.

Sandy Wong, MD, discusses the ongoing research of antibody-drug conjugates in multiple myeloma.

C. Parker Gibbs Jr, MD, discusses how to test for p16 and p21 in patients with osteosarcoma.

Ghassan K. Abou-Alfa, MD, discusses the role of ramucirumab in the treatment of patients with hepatocellular carcinoma in the second-line setting.

Praveen Ramakrishnan, MD, discusses the benefit of CAR T-cell therapy in patients with mantle cell lymphoma.

Jeff Sharman, MD, discusses the design of the phase III ELEVATE-TN trial in patients with previously untreated chronic lymphocytic leukemia.

He James Zhu, MD, PhD, discusses potential strategies to mitigate the toxicities of elective nodal irradiation in breast cancer.

Roy S. Herbst, MD, PhD, discusses the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in patients with advanced non–small-cell lung cancer (NSCLC).

Andrew Norden, MD, MPH, MBA, chief medical officer, Cota, discusses concerns surrounding cost and efficacy of molecular testing.